AMBS News .025 AMARANTUS BIOSCIENCES INC Symbol U
Post# of 144432
AMBS News .025 AMARANTUS BIOSCIENCES INC
Symbol U : AMBS
Recent Sedar Documents
Amarantus BioSciences Featured in BioWorld Today, Brewer Sports Symposium and Opportunist Magazine
2012-06-21 07:00 ET - News Release
SUNNYVALE, Calif., June 21, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing new treatments for brain-related disorders including Parkinson's disease and Traumatic Brain Injuries (TBI) centered on its proprietary anti-apoptotic therapeutic protein known as MANF, today announced that the Company was featured in BioWorld Today, Brewer Sports' 2nd Annual Sports Law and CLE Symposium and Opportunist Magazine.
On June 15th, 2012, a featured article on Amarantus was published in the NewCo News section of BioWorld Today entitled "Amarantus Restart Makes another Run at MANF Protein" and is available at http://www.bioworld.com/content/amarantus-res...nf-protein .
On Thursday, June 14th, 2012, Amarantus President & CEO Gerald Commissiong attended the Brewer Sports 2nd Annual Sports Law and CLE Symposium in Minneapolis, MN, and appeared as the biotherapeutics/athlete representative on a panel discussing the scientific, medical, legal, social and moral issues surrounding the emerging debate on how amateur and professional sports leagues should cope with the short-term and long-term impact of concussions and TBI. Other panelists included Dr. Bruce Leuchter, Associate Professor of Psychiatry at Cornell Medical College, Ross Bernstein author of "The Code: Football's Unwritten Rules and Its Ignore-at-Your-Own-Risk Code of Honor" and Michael Hausfeld, Lead Counsel for the NFL's retired players in their class-action lawsuit against the NFL.
On June 12th, 2012, Amarantus President & CEO Gerald Commissiong appeared on the cover of Opportunist Magazine, online at http://opportunistmagazine.com/gerald-commissiong-name/ .